Research to Confirm the Hemopurifier's Ability
to Remove Harmful Viruses and Exosomes From Harvested
Organs
SAN
DIEGO, June 21, 2023 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused
on developing products to treat cancer and life-threatening
infectious diseases, today announced that it is investigating the
use of its Hemopurifier® in the organ transplant market,
in addition to its ongoing studies in cancer and COVID-19.
"Our objective is to confirm that the Hemopurifier, in our
translational studies, when incorporated into a machine perfusion
organ preservation circuit, can remove harmful viruses and exosomes
from harvested organs," stated Charles J.
Fisher, Jr., M.D., Chief Executive Officer of Aethlon
Medical. "We have previously demonstrated the removal of multiple
viruses and exosomes from buffer solutions, in vitro, utilizing a
or scaled-down version of our Hemopurifier. This process
potentially may reduce complications following transplantation of
the harvested organ, which can include viral infection, delayed
graft function and rejection. We believe this new approach could be
additive to existing technologies that currently are in place to
increase the number of viable organs for transplant."
According to Precedence Research, the size of the global
transplantation market is projected to hit approximately
$33.7 billion by 2032, compared to
$15.1 billion in 2022. Further,
Precedence Research estimates that the global transplantation
market is poised to expand at a compounded average growth rate of
8.36% during the forecast period of 2023 to 2032. According to
Precedence Research, rising demand for organ transplantation to
treat organ failure and novel tissue transplantation products is
the prime factor that is driving market growth.
In the United States, all organ
transplant programs must be located in hospitals that have a
Medicare provider agreement. The ultimate goal of Aethlon Medical's
research in the transplantation area is to position the
Hemopurifier as a beneficial and potentially transformative
accessory element to existing or future organ perfusion systems
that keep harvested organs in transplantable condition.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on
developing the Hemopurifier, a clinical stage immunotherapeutic
device which is designed to combat cancer and life-threatening
viral infections. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and harmful
exosomes from blood utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where
exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA)
designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. The Hemopurifier also
holds an FDA Breakthrough Device designation and an open
Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with
approved therapies.
Additional information can be found at
www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. These
forward-looking statements are based upon Aethlon's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to
successfully complete development of the Hemopurifier and to
successfully demonstrate the utility of the Hemopurifier in the
organ transplant field, the Company's ability to manage its
clinical trials, and other potential risks. The foregoing list of
risks and uncertainties is illustrative, but is not exhaustive.
Additional factors that could cause results to differ materially
from those anticipated in forward-looking statements can be found
under the caption "Risk Factors" in the Company's Annual Report on
Form 10-K for the year ended March 31,
2022, and in the Company's other filings with the Securities
and Exchange Commission, including its quarterly Reports on Form
10-Q. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Except
as may be required by law, the Company does not intend, nor does it
undertake any duty, to update this information to reflect future
events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-investigation-of-the-hemopurifier-for-use-in-organ-transplantation-301855970.html
SOURCE Aethlon Medical, Inc.